Browse Studies — Arctuva

Phase 1

A Phase 1/2, Randomized, Controlled, Observer-Blind Study in Adults 60 Years of Age and Older to Evaluate the Immunogenicity and Safety of Different Dose Levels of a Bivalent Vaccine Candidate Against Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (HMPV)

This study is a Phase 1/2, randomized, observer-blind, active and placebo-controlled, multi-center study to be conducted in approximately 2400 adults 60 years …

Respiratory Syncytial Virus ImmunizationHuman Metapneumovirus ImmunizationHealthy Volunteers

Estimated

~$10 – $7,500